The Latest Cardiac and Vascular News
Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth SCHLIEREN, Switzerland, Jan. 9, 2023 /PRNewswire/ — DiNAQOR, a genetic medicine platform company, today announced that it has added to its leadership team with the appointments of two veteran biotechnology executives. Chris Rusconi, Ph.D., who brings […]
DiNAQOR retains option rights to own the co-developed capsids for the fields of cardiovascular and kidney disease ZURICH-SCHLIEREN, Switzerland and WESTMEAD, NSW, Australia, Jan. 10, 2022 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop […]
ZURICH-SCHLIEREN, Switzerland and LAGUNA HILLS, Calif., Sept. 23, 2021 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices. As the company grows its U.S. footprint, Mr. Dehdashtian […]
PFÄFFIKON, Switzerland, July 1, 2021 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced that it has expanded the company’s board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, M.D., Ph.D.; Steven Zelenkofske, D.O., M.S.; and Silke Rickert-Sperling, M.D. “We are extremely proud to welcome […]
PFÄFFIKON, Switzerland, Jan. 19, 2021 /PRNewswire/ — DiNAQOR, a gene therapy platform company, today announced that it has acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company. Financial terms of the transaction were not disclosed. EHT Technologies was founded in 2015 based upon research on human induced pluripotent stem cells (hiPSC) at […]
SAN RAFAEL, Calif., May 3, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment […]
SAN FRANCISCO and PFÄFFIKON, Switzerland and LONDON, Jan. 13, 2020 /PRNewswire/ — DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies, diseases of the heart muscle that can lead to heart failure in children and adults. […]
